S. Padayattil Jose

发表

Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case‐control study

V. Pengo, G. Denas, G. Zoppellaro, 2018, Cardiovascular therapeutics.

Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.

M. Corti, U. Fedeli, E. Ferroni, 2017, International journal of cardiology.

Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial

V. Pengo, A. Banzato, E. Bison, 2016, Lupus.

Warfarin prescription in patients with nonvalvular atrial fibrillation and one non–gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma

S. Testa, D. Poli, E. Antonucci, 2018, Cardiovascular therapeutics.

Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study

S. Iliceto, S. Testa, D. Poli, 2013, Journal of Thrombosis and Thrombolysis.

A Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive Procedures.

S. Testa, V. Pengo, R. Quintavalla, 2016, Journal of the American College of Cardiology.

Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome

S. Iliceto, S. Testa, C. Legnani, 2010, Journal of thrombosis and haemostasis : JTH.

Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs).

P. Carraro, G. Nante, V. Pengo, 2018, Thrombosis research.

Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile

A. Hoxha, T. del Ross, A. Ruffatti, 2013, Journal of thrombosis and haemostasis : JTH.

APS - Diagnostics and challenges for the future.

A. Hoxha, A. Ruffatti, V. Pengo, 2016, Autoimmunity reviews.

Antiphospholipid syndrome: critical analysis of the diagnostic path

A. Ruffatti, V. Pengo, A. Banzato, 2010, Lupus.

Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation

S. Iliceto, V. Pengo, G. Denas, 2015, Expert opinion on drug safety.

An unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentation

D. Ermacora, V. Pengo, G. Denas, 2012, Internal and Emergency Medicine.

Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study.

Sabino Iliceto, Paolo Gresele, Vittorio Pengo, 2011, Blood.

Antiphospholipid syndrome: antibodies to Domain 1 of β2‐glycoprotein 1 correctly classify patients at risk

A. Ruffatti, V. Pengo, A. Banzato, 2015, Journal of thrombosis and haemostasis : JTH.

Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles.

A. Hoxha, A. Ruffatti, V. Pengo, 2015, Thrombosis research.

Laboratory testing for antiphospholipid syndrome

A. Hoxha, A. Ruffatti, V. Pengo, 2016, International journal of laboratory hematology.

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation

A. Frigo, M. Plebani, C. Zambon, 2015, PloS one.

Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study.

M. Corti, U. Fedeli, E. Ferroni, 2018, International journal of cardiology.

Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation

S. Iliceto, V. Pengo, G. Denas, 2015, Expert opinion on drug safety.